3 completed, 2 recruiting, 1 terminated, 1 withdrawn. 7 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 3, Recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 2 | 5 | Recruiting 2, Completed 1, Terminated 1, Withdrawn 1 |
Follow RAD1901: new trials by email Literature Review of RAD1901 trials Research Report on RAD1901
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer Elacestrant, Trastuzumab Deruxtecan - Metastatic Breast Cancer, HER2 Low Breast Carcinoma | Phase 1 / Phase 2 | Recruiting | Kristina A. Fanucci | 65 | 2025-11-17 | 2026-06-10 |
| A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer Samuraciclib, Elacestrant Dihydrochloride - Metastatic Breast Cancer, Locally Advanced Breast Cancer | Phase 1 / Phase 2 | Completed | Carrick Therapeutics Limited | 49 | 2023-10-09 | 2026-03-23 |
| A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer Elacestrant, Onapristone - Breast Cancer | Phase 1 / Phase 2 | Withdrawn | Context Therapeutics Inc. | 2023-06-01 | 2025-04-22 | |
| A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function Elacestrant dihydrochloride - Hepatic Impairment | Phase 1 | Completed | Stemline Therapeutics, Inc. | 16 | 2023-03-13 | 2024-11-19 |
| Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer Elacestrant, Onapristone - Breast Cancer | Phase 1 / Phase 2 | Terminated | Context Therapeutics Inc. | 4 | 2022-12-02 | 2026-07-21 |
| Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer Elacestrant, Abemaciclib - Breast Neoplasms, Brain Neoplasms | Phase 1 / Phase 2 | Recruiting | Stemline Therapeutics, Inc. | 73 | 2022-08-31 | 2026-10-09 |
| Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer RAD1901 - Metastatic Breast Cancer | Phase 1 | Completed | Stemline Therapeutics, Inc. | 16 | 2016-04-01 | 2022-08-18 |
Breast Neoplasms (7) · Brain Diseases (1) · Brain Neoplasms (1) · Breast Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1)
Stemline Therapeutics, Inc. (3) · Context Therapeutics Inc. (2) · Carrick Therapeutics Limited (1) · Kristina A. Fanucci (1)
United States (6) · Belgium (2) · France (2) · Spain (2) · United Kingdom (2) · Germany (1) · Greece (1) · Italy (1) · Netherlands (1) · South Korea (1) · Turkey (Türkiye) (1)
Elisabeth GE de Vries, MD (1) · Kristina Fanucci, MD (1)
2015 (1), 2023 (1)